Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study

Diabetes Therapy

Volumn 6, Issue 2, 2015, Pages 187-196

  Ueno, Hiroaki ^a   Tsuchimochi, Wakaba ^a   Wang, Hong Wei ^a,b   Yamashita, Eiichiro ^a   Tsubouchi, Chikako ^a   Nagamine, Kazuhiro ^a   Sakoda, Hideyuki ^a   Nakazato, Masamitsu ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b DALIAN UNIVERSITY   (China)

Author keywords

Acarbose; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Insulin; Japanese patients; Miglitol; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; CREATININE; DES ACYL GHRELIN; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MIGLITOL; SITAGLIPTIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; FEMALE; GLUCOSE METABOLISM; HUMAN; IMMUNOASSAY; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 84934985957     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0113-3     Document Type: Article

References (36)

1. Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014;2:56–64.
2. Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011;2:101–21.
3. Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. 2015;5:e005892.
4. Bethel MA, Green JB, Milton J, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2015;17:395–402.
5. Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs. 2003;63:933–51.
6. Aoki K, Masuda K, Miyazaki T, et al. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J. 2010;57:667–72.
7. Goke B, Fuder H, Wieckhorst G, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995;56:493–501.
8. Ranganath L, Norris F, Morgan L, et al. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med. 1998;15:120–4.
9. Hucking K, Kostic Z, Pox C, et al. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med. 2005;22:470–6.
10. Hiki M, Shimada K, Kiyanagi T, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease—Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J. 2010;74:1471–8.
11. DeLeon MJ, Chandurkar V, Albert SG, et al. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–6.
12. Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med. 2009;26:187–8.
13. Arakawa M, Ebato C, Mita T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism. 2008;57:1299–306.
14. Narita T, Yokoyama H, Yamashita R, et al. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab. 2012;14:283–7.
15. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–35.
16. Yabe D, Watanabe K, Sugawara K, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:70–9.
17. Akamizu T, Sakura N, Shigematsu Y, et al. Analysis of plasma ghrelin in patients with medium-chain acyl-CoA dehydrogenase deficiency and glutaric aciduria type II. Eur J Endocrinol. 2012;166:235–40.
18. Seifarth C, Bergmann J, Holst JJ, et al. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med. 1998;15:485–91.
19. Enc FY, Imeryuz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol. 2001;281:G752–63.
20. Ahr HJ, Boberg M, Brendel E, et al. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung. 1997;47:734–45.
21. Lee EY, Kaneko S, Jutabha P, et al. Distinct action of the alpha-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion. J Endocrinol. 2015;224:205–14.
22. Migoya EM, Bergeron R, Miller JL, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther. 2010;88:801–8.
23. Nagai E, Katsuno T, Miyagawa J, et al. Incretin responses to oral glucose load in Japanese non-obese healthy subjects. Diabetes Ther. 2011;2:20–8.
24. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.
25. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia. 2009;52:1724–31.
26. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003;46:798–801.
27. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest. 2001;24:RC19–21.
28. Ueno H, Shiiya T, Mizuta M, et al. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocr J. 2007;54:895–902.
29. Kaku H, Tajiri Y, Yamada K. Anorexigenic effects of miglitol in concert with the alterations of gut hormone secretion and gastric emptying in healthy subjects. Horm Metab Res. 2012;44:312–8.
30. Zheng F, Yin X, Lu W, et al. Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients. J Endocrinol Invest. 2013;36:489–96.
31. Tai K, Hammond AJ, Wishart JM, et al. Carbohydrate and fat digestion is necessary for maximal suppression of total plasma ghrelin in healthy adults. Appetite. 2010;55:407–12.
32. Erdmann J, Topsch R, Lippl F, et al. Postprandial response of plasma ghrelin levels to various test meals in relation to food intake, plasma insulin, and glucose. J Clin Endocrinol Metab. 2004;89:3048–54.
33. Huang CL, Hsu CH, Huang KC, et al. Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects. Pharmacology. 2010;85:131–5.
34. Oz O, Kiyici S, Ersoy C, et al. Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes. Diabetes Res Clin Pract. 2011;94:212–6.
35. Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther. 2012;3:10.
36. Bak MJ, Albrechtsen NW, Pedersen J, et al. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol. 2014;170:529–38.